3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
4
Phase 1/2
3
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
3
Stomach Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Melanoma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumors
2
Uterine Cervical Neoplasms
1
Solid Malignancies
1
Small Cell Lung Carcinoma
1
Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
1
Ovarian Neoplasms
1
Liver Diseases
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Kidney Neoplasms
1
Kidney Diseases
1
Gliosarcoma
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
11
Nivolumab
7
Sunitinib
6
Cyclophosphamide
6
aldesleukin
5
Sorafenib
5
Everolimus
5
temsirolimus
4
belzutifan
4
atezolizumab
4
Ipilimumab
4
fludarabine
3
cabozantinib
3
Interferon-alpha
3
Gene Expression Profiling
3
Fluorouracil
3
Docetaxel
3
Cetuximab
3
Busulfan
3
valspodar
2
sargramostim
2
perifosine
2
pazopanib
2
ixabepilone
2
entinostat
2
ciforadenant
2
belinostat
2
Thiotepa
2
Temozolomide
2
Sirolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Kidney Neoplasms
×
Axitinib
×
Clear all
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts